Fellowship · Chicago, IL
Sponsored by University of Illinois College of Medicine at Chicago
Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2021 · 978 citations · Ticiana Leal
NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 2.2021.
Journal of the National Comprehensive Cancer Network : JNCCN · 2021 · 813 citations · Ticiana Leal
Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133).
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2021 · 755 citations · Ticiana Leal
Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C.
The New England journal of medicine · 2023 · 448 citations · Ticiana Leal
Eliminating Explicit and Implicit Biases in Health Care: Evidence and Research Needs.
Annual review of public health · 2022 · 307 citations · Monica Vela
First-in-Human Phase I/IB Dose-Finding Study of Adagrasib (MRTX849) in Patients With Advanced KRASG12C Solid Tumors (KRYSTAL-1).
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2022 · 277 citations ·
Comparison of the EQ-HWB and EQ-HWB-S With Other Preference-Based Measures Among United States Informal Caregivers.
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research · 2024 · 26 citations · Lisa Sharp
Pembrolizumab Plus Ipilimumab or Placebo for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%: Randomized, Double-Blind Phase III KEYNOTE-598 Study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2021 · 216 citations · Ticiana Leal